Background: Overweight and obesity is a prevalent and costly threat to public health. Compelling evidence links overweight and obesity with serious disorders such as cardiovascular diseases and diabetes. Dietary regimen are notoriously burdened with poor compliance. Chitosan is promoted in the US and other countries as an oral remedy to reduce fat absorption and has now been incorporated as a major constituent into several overthe-counter remedies. The primary aim of this study is to investigate the clinical effectiveness of oral chitosan for body weight reduction. Methods: Thirty-four overweight volunteers were included in a randomized placebo-controlled double-blind trial. Subjects were assigned to receive either four capsules of chitosan or indistinguishable placebo twice daily for 28 consecutive days. Measurements were taken at baseline, after 14 and 28 d of treatment. Subjects maintained their normal diet and documented the type and amount of food consumed. Adverse effects were assessed and compliance monitored. Results: Data from 30 subjects were entered into an intention-to-treat analysis. After four weeks of treatment, body mass index, serum cholesterol, triglycerides, vitamin A, D, E and b-carotene were not signi®cantly different in subjects receiving chitosan compared to those receiving placebo. Vitamin K was signi®cantly increased after four weeks in the chitosan group compared with placebo (P`0.05). Compliance was 91.5% and 96.0% for chitosan and placebo groups respectively. Conclusion: The above data suggest that chitosan in the administered dosage, without dietary alterations, does not reduce body weight in overweight subjects. No serious adverse effects were reported.
Introduction
Overweight and obesity presents an increasingly prevalent threat to public health. In the UK for instance, obesity has more than doubled for both genders between 1980 and 1994 (Dott, 1995 Taubes, 1998) . Figures for the US, relating to the World Health Organization (WHO, 1998) Ð classi®cation of obesity indicate a prevalence for overweight of 55% and for obesity of 22% in the adult population (Flegal et al, 1998) . Obesity has become one of the most important avoidable risk factors for morbidity (Garrow, 1992) and constitutes about 8% of all US-illness costs (around $70 billion a year) (Wickelgren, 1998; Colditz, 1992) . Compelling evidence links overweight and obesity with serious disorders, in particular cardiovascular diseases, diabetes, musculo-skeletal problems and cancer (Garrow, 1998) . These relations are causal in nature, and the risk rises with increased body mass index (BMI).
Increasing energy expenditure (for example regular physical exercise) or decreasing energy input (for example dieting) are the two principle strategies to achieve a negative energy balance and thus reduce body weight. As overweight and obesity are directly associated with total fat consumption (Astrup, 1993) the most ef®cient way to diet may be a reduction of fat intake. However, dietary regimen are notoriously burdened with poor compliance. Therefore a safe and effective medication to reduce fat absorption would be more than welcome.
Chitosan is promoted as a remedy to reduce fat absorption. It is a cationic polysaccharide derived from the cuticle of crustacea. Its properties are similar to cellulose. It is not hydrolyzable and differs from other ®bres in that it contains an amino group (Kanauchi et al, 1995) . Several lines of evidence from pre-clinical (Nauss et al, 1983; Vahouny et al, 1983 Vahouny et al, , 1988 Sugano et al, 1980; Nagyvary et al, 1979; Omrod et al, 1998) and clinical studies (Maezaki et al, 1993) have suggested that medication with oral chitosan might help to reduce body weight. Double-blind, randomized, placebo-controlled trials also suggest the reduction of body weight when given in addition to hypocaloric diets for four weeks (Colombo & Sciutto, 1996; Veneroni et al, 1996; Macchi, 1996; Giustina & Ventura, 1995; Sciutto & Colombo, 1995) . Chitosan has now been incorporated as a major constituent into several over-the-counter remedies for overweight and obesity available in the US and other countries. However, its clinical effectiveness for this condition remains disputed. The primary aim of this study is to investigate the clinical effectiveness of oral chitosan for body weight reduction in overweight patients when given in the absence of dietary alterations.
Methods
This study was designed to exclude a treatment effect greater than 3 kg over a 28 d study period with a power of 80%, a beta error of 0.2 and an alpha error of 0.05. The study was advertised in the local press and invited overweight subjects to participate in a weight reduction trial. Subjects were included in a double-blind, randomized placebo-controlled trial (RCT) if aged between 18 and 60 y, BMI ranging from 23.9 ± 28.5 kgam 2 for women and 25.0 ± 29.9 kgam 2 for men (Hill & Roberts 1996) . Exclusion criteria were intestinal disorders, diabetes mellitus (as de®ned by positive urine glucose test), concomitant medication, pregnancy or known or suspected hypersensitivity to any component of the drug. All volunteers had given informed, written consent. The study was approved by the University of Exeter Research Ethics Committee and conducted between October ± December 1997. Block randomization, using random number tables was performed by an individual not involved in the study. The randomization code was kept in a sealed, opaque envelope and broken only after conclusion of the experimental phase of the trial.
Subjects were randomized to receive either four capsules of chitosan (250 mg deacetylated chitin biopolymer per capsule) or indistinguishable placebo twice daily for 28 consecutive days. Subjects were advised to maintain their normal diet and to record the type and amount of food consumed in the food diary provided. Subjects visited the study centre three times: at baseline, after 14 and 28 d of treatment. At baseline medical history was assessed and a urine sample taken for routine glucose measurement. At each study visit body weight, height, blood pressure and quality of life using the SF-36 (Jenkinson et al, 1993) were assessed. Blood samples were taken at all visits to measure total cholesterol, triglycerides, vitamin A, D (as 25-hydroxy vitamins D 2 and D 3 ), E, and K, and b-carotene. Fat soluble vitamins and b-carotene were assessed using high performance liquid chromatography (HPLC) procedures. Type and frequency of adverse effects (AEs) were assessed and compliance was monitored by counting the remaining capsules after the ®nal study visit.
Statistics t-Tests for independent samples were used to compare differences between intervention and control group at baseline. The w 2 -test was used for intergroup differences in sex distribution. Analysis of variance (ANOVA) and the Duncan multiple range test were used to compare intervention and control values at each visit and between visits (SPSS Statistics, Chicago, Il, US). The null-hypothesis was rejected when P was below 0.05.
Results
Thirty-four overweight volunteers, 28 women and 6 men were included into the study. Four subjects (chitosan: n 2, placebo n 2) withdrew from the study after the ®rst study visit and were excluded from the data analysis. Data of 30 subjects (chitosan: n 15, placebo n 15) were entered into an intention-to-treat analysis. Baseline characteristics were not signi®cantly different for subjects in the chitosan group compared with placebo (age: mean (s.d.) 46.7 (8.8) and 41.3 (11.3) respectively; gender: maleafemale 2a13 and 4a11 respectively). Table 1 gives values at baseline, after two weeks and four weeks of treatment. After four weeks of treatment, vitamin K was signi®cantly higher in subjects receiving chitosan compared with placebo. No other parameters showed signi®cant within-group or intergroup differences at any of the time points (Table 1) . Assessment of quality of life using the SF-36 showed no clinically relevant differences between both groups. Minor AEs were reported by nine subjects receiving chitosan and four receiving placebo. Subjects most frequently complained about constipation, reported by six and two subjects in the chitosan and placebo group respectively. No dropouts were necessitated by AEs. Compliance was 91.5% and 96.0% for chitosan and placebo groups respectively.
Discussion
The notion that chitosan may reduce body weight in overweight and obese subjects has prompted its incorporation as a major constituent into several over-the-counter remedies. Indeed, several previous double-blind RCTs have suggested that chitosan can signi®cantly reduce mean body weight compared with placebo when both are given together with a hypocaloric diet (Colombo & Sciutto 1996; Veneroni et al, 1996; Macchi, 1996; Giustina & Ventura, 1995; Sciutto & Colombo, 1995) . The implication of these results is that oral medication with chitosan may result in weight loss without the reduction of energy intake. To our knowledge the present trial is the ®rst RCT to determine the effects of chitosan when given in the absence of dietary alterations. It found no clinically relevant reduction of body weight compared to placebo. 
Trial of chitosan for body weight reduction MH Pittler et al
Several factors may be responsible for the above ®nd-ings. One is that the given dosage was insuf®cient to reveal clinically relevant effects. Although the recommended dosage of chitosan is 2 ± 3 gad, the equivalent dose found to be effective for weight reduction in animal experiments is 15 ± 22 times higher (Garrow, 1997 ). An analysis of the medication used in this trial (performed by the sponsors after the results were available) shows that the capsules contained 42% chitosan; less than the 71% (250 mg) stated by the distributor. It is conceivable that this percentage difference has contributed to the above results. Furthermore, it is conceivable that increased awareness of body weight may have in¯uenced eating habits. However, all volunteers were asked to remain on their usual diet and to keep it constant throughout the trial. All subjects documented total food intake per day over the 28 d study period and returned the food diaries for inspection. Due to the doubleblind design using indistinguishable placebo, similar changes of eating habits are also likely to have occurred in both, chitosan and placebo groups. A further problem relates to the evidence used as a rationale for the present investigation. Previous investigations administered chitosan together with a hypocaloric diet (Colombo & Sciutto, 1996; Veneroni et al, 1996; Macchi, 1996; Giustina & Ventura, 1995; Sciutto & Colombo, 1995) . Statistical pooling of the results of these studies all supplying a diet of 1000 ± 1200 kcalad, suggests a mean body weight reduction by an extra 3.3 kg in the chitosan group compared with placebo (Ernst & Pittler, 1998) . With respect to the proposed mechanism of action, this would require a faecal fat loss of more than 100 gad (Garrow, 1997) . This seems implausible since the supplied diet would not normally contain 100 g fat. Therefore, other mechanisms than faecal fat excretion would be required for the observed weight reduction to occur. These considerations are in keeping with the results of the present trial particularly with the assessment of fat soluble vitamins and b-carotene. Despite the differences in the vitamin K assessment, ®gures were similar as previously reported for healthy individuals .
Conclusions
The above data suggest that chitosan at the administered dosage and without dietary alteration does not reduce body weight in overweight subjects. No serious adverse effects of chitosan were reported. Randomised controlled trials assessing chitosan at higher dosages are needed to clarify the issue.
